PB0039 - The Key Role of Plasminogen Activator Inhibitor-1 (PAI-1) in the Thrombogenesis Difference in COVID-19-associated Pneumonia Compared to Bacterial Pneumonia

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

KB

Kseniia Bielosludtseva

Assistant professor
Dnipropetrovsk State Medical Academy
Dnipro, Dnipropetrovs'ka Oblast', Ukraine

Co-Author(s)

TP

Tetiana Pertseva

Rector
Dnipropetrovsk Medical Academy
Dnipro, Dnipropetrovs'ka Oblast', Ukraine

Background: PAI-1 plays a key role in a wide range of physiological and pathological processes, including coagulation, fibrinolysis, inflammation.

Aims: The aim was to estimate the diagnostic role of PAI-1 on admission in hospitalized patients with COVID-19 pneumonia, comparing with bacterial pneumonia.

Methods: We observed 3 groups: Main (1) – 85 patients (mean age – 59 (52; 65) years, men – 45 (52.9%)), hospitalized with pneumonia on the background of laboratory-confirmed (PCR) COVID-19, divided into 3 subgroups: subgroup 1 – 40 patients with moderate COVID-19, subgroup 2 – 25 patients with severe COVID-19, subgroup 3 – 20 patients with critical COVID-19; Comparative (2) – 55 patients (mean age – 48.9 (34; 62) years, men – 30 (54.5%)), hospitalized with community-acquired pneumonia of bacterial etiology (CABP) without COVID-19; Control (3) – 25 healthy volunteers (average age – 50.0 (35; 65) years, men – 13 (52.0%)). General analysis, plasma level of PAI-1 (Human PAI-1 ELISA Kit, Elabscience) performed at admission before starting of anticoagulant treatment, statistical analysis.

Results: At admission the highest level of PAI-1 (6.1 [0.15; 18] ng/ml) was in COVID-19 patients (Main group) and exceeds the Control group (0.1 [0.09; 0.11] ng/ml), р1-3=0,000) in more than 60 times. Whereas the level of PAI-1 in patients with CABP didn’t differ from Control group (0.1 [0.09;0.11] ng/ml), р2-3=0,29) (Fig.1).Among COVID-19 group the levels of PAI-1 correlated with the disease severity (Fig.2).

Conclusion(s):

Conclusions: 1) significantly increase of plasma levels of PAI-1 in COVID-19 pneumonia demonstrates the cornerstone in thrombogenesis of this disease – problems in fibrinolysis system, which is the main difference between CABP;
2) in hospitalized patients with COVID-19 pneumonia the level of PAI-1 is associated with the disease severity and could be the crucial marker for patients’ distribution.